Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.
Elyssa DenaultErika NakajimaVivek NaranbhaiJennifer A HutchinsonLindsey MortensenElizabeth NeihoffCaroline BarabellAmy ComanderDejan JuricIrene KuterTheresa MulveyJeffrey PeppercornAron S RosenstockJennifer ShinNeelima VidulaSeth A WanderBeverly MoyLeif W EllisenSteven J IsakoffA John IafrateJustin F GainorAditya BardiaLaura M SpringPublished in: Therapeutic advances in medical oncology (2022)
Most patients with breast cancer generate detectable anti-spike antibodies following SARS-CoV-2 vaccination, though systemic treatments and vaccine type impact level of response. Further studies are needed to better understand the clinical implications of different antibody levels, the effectiveness of additional SARS-CoV-2 vaccine doses, and the risk of breakthrough infections among patients with breast cancer.